FASENRA (BENRALIZUMAB) (PREFERRED) PRIOR AUTHORIZATION FORM





(form effective 1/9/2023)

Fax to PerformRx[™] at **1-888-981-5202**, or to speak to a representative call **1-866-610-2774**.

PRIOR AUTH	IORIZATION REQUES	T INFORMATION										
□ New request □ Renewal request total # pages:				Name of office contact:								
Contact's phone number:				LTC facility contact/phone:								
PATIENT INF	ORMATION											
Patient name:				Patient II	D #:				DOB:			
Street address:							ity/state/zip:					
PRESCRIBE	R INFORMATION											
Prescriber name:				Specialty	/:							
State license #:							MA Provider ID #					
Street address:				Suite #: City			ity/state/zip:					
Phone:				Fax:								
CLINICAL IN				1								
	ested: Fasenra 30 mg/ml syr	ringe 🛛 Fasenra 30 mg/ml a	utoiniecto	⊡ Fase	onra							
Dose/directions:			latonijootoi		////u							
Quantity requested	l: # syringes (30 mg/m	l)			Duratio	on requested	1:	months	Weight:		lbs / kg	
Diagnosis:		,						 D:	x code (required):		0	
PHARMACY	INFORMATION (Prese	criber to identify the pr	armacy	that is t	n disr	hense the	medic	ation).				
Deliver to: □ Patie						Sense the	meare	aciony				
Pharmacy Phone #	, ,			Pharmac	v Fax #:							
		pharmacy chosen for delivery o	of this med									
INITIAL REQ	LIESTS											
1. Is Fasenra being prescribed by or in consultation with a specialist, such as a pulmonologist?							🗆 No	Provide s	pecialty:			
 Is the patient being precented by an echedulation mark speciality, even do a paintenergiet. Is the patient being treated for a diagnosis of asthma that is severe despite use of tolerated asthma controller medications? 						er 🗆 Yes			ocumentation.			
3. Does the patient have asthma of an eosinophilic phenotype with an absolute blood eosinophil count \geq 150/microliter?						□ Yes	□ Yes □ No Eosinophil count: Date of result:					
							Yes – List medications being used:					
4. Will Fasenra be used in addition to standard asthma controller medications (e.g., inhaled corticosteroids, inhaled LABAs, etc.)?						🗆 No						
							Submit medical record documentation of patient's					
							medication regimen and response to treatment.					
RENEWAL R	EQUESTS											
1. Has the patient experienced measurable evidence of improvement in asthma severity?						□ Yes	🗆 No	Submit do therapy.	ocumentation of patie	ent's respons	e to	
							List medi	cations bei	ng used:			
		ed in addition to standard asthma controller medications (e.g., inhaled			🗆 No							
corticosteroids,	nhaled LABAs, etc.)?						Submit medical record documentation of patient's medication regimen and response to treatment.					
3. Is Fasenra being prescribed by or in consultation with a specialist, such as a pulmonologist?						□ Yes						
PI FASE FAX		WITH REQUIRED CLIN		OCUME	ΝΤΔΤ							
Prescriber signatu			ing te b						Date:			

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.